Commercial Prophylactic Product Testing Using Endemic Bacterial Pathogen Library. Led at WRAIR-Africa by Elizabeth Odundo, the purpose of this project is to test commercial prophylactic products (The Immuron Ltd.) Hyperimmune Bovine Colostrum (HBC) product, Travelan® (and the Lumen Bioscience oral prophylactic single-chain VHH antibodies/nanobodies) against diarrheal diseases for efficacy against global strains. This research project is a collaboration with the Bacterial Diseases Branch at WRAIR headquarters.

Controlled Human Challenge Study for Shigella. Led at WRAIR-Africa by Dr. Melissa Kapulu and Dr. Fredrick Sawe, the purpose of this project is to translate the model based on the S. sonnei 53G challenge strain utilizing the lyophilized product to an endemic adult population, in Kenya, to enable the utilization of the model for vaccine efficacy testing in Kenya or similar endemic settings. This research project is a collaboration with Microbiology Hub Kericho (MHK).

Bacteriophage Treatments for Wounded Soldiers in Austere Environments. Led at WRAIR-Africa by Dr. Lilian Musila, the purpose of this project is to incorporate the bacteriophages into proprietary platforms for delivery to soldiers wounded in austere environments. This research project is a collaboration with Memsel through MTEC and CDMRP.

Institut Pasteur SF2a-TT15 Conjugate Vaccine Clinical Trial. Led at WRAIR-Africa by Dr. Armelle Phalipon and Dr. Fredrick Sawe, the purpose of this research project is to investigate the safety and immunogenicity of the SF2a-TT15 conjugate vaccine against S. flexneri 2a in adults, children, and infants, in endemic countries. This research project is a collaboration with MHK.

GSK 4-Component GMMA Vaccine Clinical Trial. Led at WRAIR-Africa by Dr. Deborah Langat, the purpose of this research project is to evaluate safety and immune responses to the GVGH altSonflex1-2-3 vaccine against shigellosis in adults, children, and infants. This research project is a collaboration with MHK.

TREAT TD 2.0 Diarrhea Therapeutic Studies Testing. Led at WRAIR-Africa by Dr. Musila, the purpose of this project is to assess the use of a single dose rifaximin and loperamide treatment for diarrhea. This research project is a collaboration with IDCRP and the British Army.

Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers. Led by Dr. Walter Otieno, the purpose of this project is to demonstrate the clinical efficacy of RSVt vaccine for the prevention of RT-PCR confirmed RSV LRTD, after 2 doses over RSV Season 1.

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease (SCD). Led by Dr. Janet Oyieko, the purpose of this research project is to determine the recommended Phase 3 dose of mitapivat by evaluating the effect of 2 dose levels of mitapivat versus placebo on anemia in subjects with SCD and Safety.

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease. Led by Dr. Janet Oyieko, the purpose of this project is to assess the efficacy of etavopivat as compared to placebo on the annualized vaso-occlusive crisis (VOC) rate.